

Index

- accelerated aging, 79, 138, 214, 243
- Accountable Care Organizations (ACOs), 21
- ACHIEVE program, 182–83
- active coping, 201, 203
- ADAPT-ITT method, 170
- Adult Protective Services, 227
- adversity, lifelong experience of, 204–6
- Affordable Care Act (ACA), 22, 230
- African-Americans
 psychotic symptoms, 27
 schizophrenics in nursing homes, 18
- age
 nursing home
 schizophrenia residents, 18
 quality of life and, 123
 age of exposure/outcomes, 2
 aging. *See also* late life psychosis; late life schizophrenia
 accelerated, 79, 138, 214, 243
 across cultures, 219
 antipsychotic related
 movement disorders and, 61–63
 brain, and schizophrenia, 56
 caregivers, 192–93
 metabolic syndrome and, 63–64
 non-uniformity of, 200
 pharmacodynamics and, 157
 pharmacokinetics and, 157
 response to antipsychotics, 146
 schizophrenia and, 55, 63–64
 schizophrenia, biomarkers in, 58–60
 successful, 96, 101, 124
- aging individuals with schizophrenia (AIWS). *See* late life schizophrenia
- aging-out, caregivers, 197
- agitation, 30
- Alzheimer's disease
 cognitive decline, 70
 psychotic symptoms, 33
 VBR measure, 55
- amotivation, 114
- antidepressants, 35, 130
- antipsychotics, 147
 antidepressants with, 130
 bipolar disorder and, 40
 cancer and, 86
 cardiovascular disease and, 84, 161
 dementia and, 34–35, 160
 diabetes and, 83
 dosing of, 161–62
 drug–drug interactions, 159, 160
 effects of long term exposure, 60
 life expectancy and, 224
 maximising compliance, 162
 metabolic problems with, 21
 mortality risk, 34
 movement disorders and, 61–63
 older adult studies, 148
 public policy issues, 229
 RCTs, 244
 reducing/minimizing medication, 162
 respiratory diseases and, 82
 schizophrenics in nursing homes, 18
 serious side effects and safety concerns, 160–61
 side effects, 157–60, 205, 215, 223
 treatment, 37
 treatment, first line of, 146–47
- APA guidelines, dementia treatment, 33
- APOE epsilon-4, 58
- aripiprazole, 35, 37, 155
 dosing, 162
- asenapine, 156, 159
- Assertive Community Treatment (ACT), 142, 231
- Assistant Secretary DHSS, 234
- Assisted Outpatient Treatment (AOT), 195
- auditory hallucinations, 33
- autoimmune disease, 50
- avoidant (passive) coping, 201, 203
- avoiding disease and disability domain, 99, 100
- Ayurvedic medicine, 216
- Beautiful Mind, A (movie), 113
- Beers Criteria, 160
- behavioral tailoring, 172
- biomarkers, 3
 aging in schizophrenia, 58–60
- bipolar disorder, 39–40, 83
- birth cohort, 3
- body mass index (BMI), 180, 181
- brain aging, schizophrenia, 56
- breast cancer, 86
- brief psychotic disorder, 31
- bronchitis, 82
- Calgary depression rating scale (CDRS), 131
- Camberwell Assessment of Need for the Elderly (CANE), 137
- cancer, 85–86, 89
 incidence rates, 85
 mortality risk, 85
 cancer screening gaps, 86
- carbamazepine, 159

- Cardinal Needs Schedule, 137
 cardiovascular disease, 58, 63, 83–84
 antipsychotics and, 84, 161
 mortality rates, 83, 89, 139
 prevalence rates, 84
 caregivers, 190–98, 224, 245.
 See also families
 aging, research findings on, 192–93
 aging-out of, 197
 agreeable patient, 190
 Assisted Outpatient
 Treatment, 195
 dementia and, 33, 34
 developing countries, 214–15, 245
 difficult and violent patient, 191
 family support, 233
 international picture, 195–96
 living with family, 227
 non-assaultive crises, 191
 parental, 192–93
 planning for the future, 193, 194
 psychological costs, 192
 services assisting, 194
 sibling, 194
 spousal, 194
 Carers' Trust, 197
 case/care management, 233
 case-control studies, 1, 3, 8, 82
 catatonia, 27
 catechol-*O*-methyltransferase (COMT), 57
 CATIE study, 84, 147
 CCR5 gene, 50
 Center for Epidemiologic Studies - Depression Scale (CESD), 98
 cerebrovascular risk score, 39
 China
 caregivers in, 195, 214
 new technologies, 218
 chlorpromazine, 61, 148
 cholinesterase inhibitors, 34
 Chronic Disease Self-Management Program (CDSMP), 170, 171, 184
 chronic obstructive pulmonary disease (COPD), 82
 CiTAD trial, 35
 citalopram, 35, 72, 131
 clinical epidemiology, 28–29
 clinical outcome, 2
 clinical recovery, 104
 clinical remission, 100, 101, 103
 clinician ratings, 118
 clozapine, 35, 131, 147, 148, 157
 comparison drug, 150
 dosing, 162
 metabolic syndrome and, 63
 selected studies, 149
 clubhouses, 140
 cognition and function, 121
 domain, 100
 late life schizophrenia, 72–73
 Cognitive Behavioral Social Skills Training (CBSST), 73, 114, 176–78
 cognitive behavioral therapy (CBT), 176, 245
 cognitive dysfunction
 early-onset schizophrenia, 49, 243
 late-onset schizophrenia, 49
 longitudinal studies, 69–71
 outcome domain, 97, 98, 103
 profile, in late life schizophrenia, 71–72
 schizophrenia, 57, 69
 VLOSLP, 49
 cognitive outcome, 103
 cognitive remediation, 73, 245
 collaborative care models, 21, 87
 co-located models, 87
 colon cancer, 86
 community acceptance, 231, 232
 community integration, 105, 120
 criteria, 104
 Community Integration Scale, 99, 100
 community residences, 227
 community studies, 27
 cognitive decline, 70
 outcome in schizophrenia, 96, 99
 social functioning, 118–25
 community treatment needs, 135–43
 assessment of, 136–37
 case study, 135
 domains, 138–40
 meeting, 140–42
 studies of, 137–38
 unmet needs, 136
 comorbidities, 29, 214
 cancer, 85–86
 cardiovascular disease, 83–84
 depression, 128
 diabetes, 82–83, 171
 late life schizophrenia, 79–81, 88–89, 170
 prevalence of, 169
 respiratory disorders, 81–82
 competing risks, 3
 Confusion Assessment Method (CAM), 32
 congruent psychotic symptoms, 39
 content analysis, interviews, 202
 coping skills training, 173
 coping strategies, 114, 201, 203–4
 coronary heart disease (CHD), 63, 83, 84, 139
 cost of living adjustment, 226, 227
 C-reactive protein (CRP), 50
 crisis situations, 191
 cross-sectional studies, 1, 8, 97, 100, 105, 123
 CT scanning, 55
 cultural-comparative studies, 212
 cytochrome P450 (CYP) enzymes, 159
 data collection, 202
 day care facilities, 125
 daytime activities, 140, 141
 De Hert, M., 88
 deinstitutionalization, 15, 119, 197
 delirium, 31, 30–32
 behavioral symptoms, 30
 motor subtypes, 32
 preventative strategies, 32
 timeline of change, 32
 delusional disorder, 31, 38
 delusions, 4, 27, 213
 Alzheimer's disease, 33
 delirium, 30
 dementia, 33
 dementia, 32–35, *See also* Alzheimer's disease

- antidepressants and, 35
 antipsychotics and, 34–35, 160
 cholinesterase inhibitors, 34
 late life psychosis
 association, 8
 non-pharmacologic approaches, 33
 VLOSLP and, 49, 242
 dementia praecox, 95
 Dementia Rating Scale (DRS), 71, 98
 depression, 128–32
 outcome, 103
 outcome domain, 97, 98, 102
 outcome indicator, 105
 overview of symptoms, 128–29
 pharmacotherapy, 130–31
 psychosocial treatment, 131
 quality of life and, 123, 130
 social indicator scores, 119
 deprivation, schizophrenia and, 201
 Determinants of Outcome of Severe Mental Disorder (DOSMeD), 218
 deutetrabenazine, 161
 developing countries, 212–20
 caregivers, 214–15, 245
 cross-cultural differences in treatment, 215–17
 future directions for research, 218–19
 innovative technologies, 217–18
 late life schizophrenia, 213–14, 214–15
 outcome of schizophrenia, 246
 schizophrenia across cultures, 212–13
 diabetes, 82–83, 88, 171
 mortality risk, 82
 prevalence rates, 83
 diet
 healthy eating, 179, 180, 182
 poor, 179
 diffusion tensor imaging (DTI), 50
 dimensional framework, DSM-5, 97–98
 disease burden, 1
 disorganized thinking, 27
 divalproex, 39
 Dixon, Lisa, 20
 dopamine receptor blockade, 61, 146, 158, 159
 dopamine receptors, binding, 157
 DRESS syndrome, 161
 drug–drug interactions, 159, 160
 Druss, B.G., 170
 6 “D’s” disorders, 28
 DSM-5, 27
 bipolar disorder, 39
 delusional disorder, 38
 dementia, 33
 dimensional framework, 97–98
 dimensionless approach, 243
 psychosis symptom severity, 97
 psychosis with MDD, 39
 psychotic disorders, 7
 schizophrenia diagnosis, 36
 schizophrenia subtypes, 47
 social functioning, 117
 subsyndromal depression, 129
 duration of exposures, 2
 early-onset schizophrenia, 36, 51
 cognitive defects, 49, 243
 demographics, 47
 genetics/heritability, 50
 inflammation and, 50
 neuropathology/neuroimaging, 49
 positive and negative symptoms, 48
 ECT (electroconvulsive therapy), 39, 162
 emotional management, 170
 engagement with life domain, 100
 environmental needs, 138
 Epidemiologic Catchment Area (ECA)
 study, 14
 epidemiology, 1–2, 27–29
 clinical epidemiology, 28–29
 defining psychosis in studies, 3–5
 late life psychosis, 5–8
 late life schizophrenia, 13–15
 observational studies, 1, 2–3
 essence of life, schizophrenia as, 203
 estrogen, 48
 estrogen theory, 48
 ethnicity
 cancer rates, 85
 psychotic symptoms, 27
 schizophrenia hospital populations, 16
 schizophrenics in nursing homes, 18
 treatment problems and, 229
 executive dysfunction, 71
 exercise. *See* physical activity
 extrapyramidal side effects (EPS), 62, 147, 157
 families
 dementia and, 33
 living with, 227
 rejection by, 205
 substitute, 208
 family psychoeducation (FPE), 197
 family support, 192, 233
 FDA black box warning, 34, 161, 229
 financing, 22–23
 care in developing countries, 215
 income supports, 226
 meeting needs, 142
 nursing homes, 232
 treatment, 230
 first generation antipsychotics, 34, 62, 147
 older adults, 147
 side effects, 157
 first line of treatment, 146–47
 fluphenazine, 147, 148, 159
 food stamps, 226
 fractional anisotropy, 50
 Framingham study, 63, 84, 87
 frontal lobe activity, reductions, 57
 Functional Adaptation Skills Training (FAST), 175–76
 functional MRI (fMRI), 57
 funding. *See* financing
 gender
 caregivers and, 192, 193
 onset of schizophrenia and, 47

- gender (*cont.*)
 risk factors for late life psychosis, 6
 social functioning and, 122
 genetics, schizophrenia, through life, 57–58
 Geriatric Depression Score (GDS), 129
 GERI-BD trial, 39
 globalization, 246
 Granholm, E., 177
 growth, in late life schizophrenia, 206–8
 guns, access to, 225
 hallucinations, 4, 27, 213
 auditory, 33
 delirium, 30
 dementia, 33
 visual, 33, 212
 haloperidol, 147, 148
 Hamilton Depression Rating Scale, 129, 131
 Health and Recovery Peer (HARP), 170–71, 184
 health care registers, 5
 health care utilization, 86–88, 89
 Health Homes, 21, 233
 health professionals, shortage of, 246
 health promotion models, 179–83, 185
 ACHIEVE, 182–83
 InSHAPE, 180–81
 STRIDE, 179–80
 Healthcare Cost and Utilization Project (HCUP), 16
 healthy eating, 179, 180, 182
 Helping Older People Experience Success (HOPES), 174–75, 184
 hepatic function, 159
 herbal supplements, 159
 heterogeneity of course, 106
 high cognitive and physical function domain, 100
 HIPAA rules, 192
 HIV/AIDS, 225
 homelessness, 225, 226
 hospital records, 5
 hospitalization, 82, 205
 long-term, 228
 hospitals, 16
 characteristics of discharges from, 17
 housing, 237
 housing costs, 226, 227
 housing issues, 226–28
 housing programs, 223
 hs-CRP biomarker, 58, 244
 5HT_{2A} receptors, 157
 hyperactive delirium, 32
 hypoactive delirium, 32
 hypoactive/hyperactive delirium, 32
 IL-6 biomarker, 59
 illness self-management, 170, 184
 HARP program, 170–71, 184
 I-IMR program, 172–73, 184
 TTIM program, 171–72, 184
 income supports, 226
 incongruent psychotic symptoms, 39
 independent living, 99, 227
 India, 196, 213, 216
 Individual Placement and Support (IPS), 114
 individualized care, 246
 inflammation, 50
 neuroinflammation, 63
 information
 gathering, 4–5
 unmet need, 139
 information processing
 impairments, 71
 inpatient sector, 15–16
 inpatient treatment, 228
 InSHAPE program, 180–81
 institutionalization, 70
 cognitive decline and, 70
 worsening of symptoms, 214
 integrated care, 229
 Integrated-Illness
 Management and Recovery (I-IMR), 172–73, 184
 International Late-Onset Schizophrenia Group, 47
 International Pilot Study of Schizophrenia (IPSS), 218
 International Study of Schizophrenia (ISoS), 218
 Iran, caregivers in, 196
 isolation. *See* social isolation
 jails, 227, 228
 Kinect for Xbox 360 game system, 183
 Kraepelin, E., 95
 lack of insight, 4
 late life psychosis, 146, *See also* psychosis
 antipsychotic studies, 148
 assessment and diagnosis, 27–30, 30–41
 dementia association, 8
 diagnosis, comorbidities, 29
 differential diagnosis, 30
 epidemiology of, 5–8, 27–29
 examination and laboratory assessment, 29–30
 first generation
 antipsychotics, 147
 incidence of, 6
 mortality rates, 8
 prevalence of, 5, 7, 28
 risk factors, 6, 28, 29
 second generation
 antipsychotics, 157
 late life schizophrenia, 13, 200, 242–48. *See also* schizophrenia
 cancer and, 85–86, 89
 cardiovascular disease and, 83–84, 89
 clinical and social needs, 246
 cognition and function in, 72–73
 community needs. *See* community treatment needs
 comorbidities, 79–81, 88–89, 170
 depression in. *See* depression
 developing countries. *See* developing countries
 diabetes and, 82–83, 88, 171
 diagnosis, 242
 ECT, 162
 experience of growth, 206–8
 financing, 22–23
 future research needs, 235–36

- health care utilization, 86–88, 89
 health promotion models, 179–83, 185
 illness self-management, 170–73, 184
 inpatient sector, 15–16
 model programs/
 interventions in the
 future, 183–85
 morbidity rates, 20
 non-pharmacologic
 treatment, 38
 nursing homes, 17–20
 outcomes. *See* outcome in
 schizophrenia
 outpatient care, 20
 physical health care, 20–22
 prevalence, trends in,
 13–15, 169
 psychosocial rehabilitation,
 173–78, 184
 respiratory disorders and,
 81–82, 88
 social functioning. *See*
 social functioning
 subjective accounts of. *See*
 subjective accounts
 treatment, 37
 late-onset schizophrenia, 31,
 36, 37, 47, 51
 cognitive defects, 49
 demographics, 47
 developing countries, 213
 diagnostic status, 47
 genetics/heritability, 50
 inflammation and, 50
 neuropathology/
 neuroimaging, 49–50
 positive and negative
 symptoms, 48–49
 sensory deficits, 50
 treatment, 51
 Lewy body disease
 antipsychotic side effects, 35
 psychotic symptoms, 33
 life expectancy
 psychosis, 223, 224
 public policy goal, 236
 schizophrenia, 79, 169
 life review, 209
 lithium, 39
 living with family, 227
 longitudinal studies, 1, 3
 cognitive functioning,
 69–71
 outcome domains, 102–5
 predictors and trajectories,
 103
 loxapine, 148, 157
 lung cancer, 85, 86
 lurasidone, 156, 159
 major depressive disorder
 (MDD), 38–39
 major depressive episodes,
 129
 major neurocognitive
 disorder, 31
 major vascular neurocognitive
 disorder, 33
 mania, antipsychotic
 treatment, 40
 Medicaid, 22, 230
 funding nursing homes,
 22, 232
 restructuring, 237
 medical disorders. *See specific
 medical disorder*
 medical management, 170
 Medicare, 20, 22, 230
 Part D, 22
 restructuring, 237
 Medicare Improvements for
 Patients and Providers
 Act (MIPPA), 23
 memantine, 34
 memory deficits, 71
 men. *See* gender
 Mental Health Parity and
 Addiction Equity Act of
 2008, 22
 mental health services
 drift to long term care,
 232
 meeting needs, 140, 141
 shortage of providers,
 215
 unengagement with, 142
 mental illness. *See specific
 mental illness*
 mentors, 207
 Meriden Family Programme,
 197
 Met allele, 57
 met needs, 136
 metabolic syndrome, 61,
 63–64
 microglial activation, 60
 mild neurocognitive disorder,
 31
 mind cure, 112
 Mini-Mental State
 Examination (MMSE),
 70, 71
 Minimum Data Set (MDS), 18
 mirror sign, 33
 misidentification, 33
 mobile technologies, 87, 185,
 217, 248
 model programs
 ACHIEVE, 182–83
 FAST, 175–76
 future directions/
 recommendations,
 183–85
 HARP, 170–71, 184
 health promotion, 179–83,
 185
 HOPES, 174–75, 184
 I-IMR, 172–73, 184
 illness self-management,
 170–73, 184
 InSHAPE, 180–81
 PEDAL, 176
 psychosocial rehabilitation,
 173–78, 184
 STRIDE, 179–80
 TTIM, 171–72, 184
 Moos' Ecosystem Model, 99
 Morse's principles, 202
 mortality
 antipsychotics and, 34
 cardiovascular disease, 83,
 89, 139
 caregivers and, 193
 dementia patients,
 antipsychotics and, 161
 diabetes, 82
 drug–drug interactions
 and, 159
 late life psychosis, 8
 late life schizophrenia,
 79–81
 respiratory disorders, 81
 risk, 85
 schizophrenia, 6, 20, 79
 mortality gap, 224–26, 236
 motivation, unmet needs and,
 143
 movement disorders,
 antipsychotic related,
 61–63
 MRI scanning
 fMRI, 57
 onset of schizophrenia and,
 49
 schizophrenia, 56

- Nash, John, 113, 190
 National Alliance on Mental Illness (NAMI), 192, 193, 195, 196, 198
 National Comorbidity Survey Replication (NCS-R), 14, 38, 39
 National Inpatient Sample (NIS), 16
 National Institute of Mental Health (NIMH), 59, 235
 need domains, 138–40
 environmental, 138
 physical, 138
 psychological, 139–40
 social, 140
 needs
 assessment, 136–37
 meeting, 140–42
 met, 136
 unmet. *See* unmet needs
 negative symptom domains, 97, 98
 neurocognitive disorders, 28.
 See also dementia
 early-onset schizophrenia and, 243
 major, 31
 major vascular, 33
 neuroimaging
 early and late onset schizophrenia, 49
 functional, 56
 schizophrenia, 55–56
 neuroinflammation, 63
 neuroleptic malignant syndrome (NMS), 161
 neuropathology
 early and late onset schizophrenia, 49
 schizophrenia, 60
 New Club, The, 141–42
 non-affective psychoses (NAP), 14
 non-motor delirium, 32
 non-primary diagnosis of schizophrenia
 hospital populations, 16
 normalization, 207, 208
 nursing homes, 17–20
 cognitive decline and, 70
 financing through Medicaid, 22
 funding, 232
 mental illness admissions, 169
 polypharmacy interactions, 159
 resident characteristics, 19
 obesity, 179, 180, 181, 182, 224
 neuroinflammation and, 63
 OBRA-87 legislation, 17, 18
 observational epidemiology studies, 1, 2–3
 observer-based ratings, 117, 118
 olanzapine, 35, 37
 cardiovascular risks, 84
 cognition study, 72
 comparison drug, 154
 dosing, 162
 selected studies, 153
 older adults. *See* aging; late life psychosis; late life schizophrenia
 orofacial dyskinesia, 61
 outcome in schizophrenia, 95–96, 107
 correlation of indicators over time, 105
 developing countries, 246
 DSM-5 dimensional framework, 97–98
 heterogeneity of course, 106
 historical rates, 95
 methods, 96
 paradoxical aging and, 106
 positive mental, 113
 recovery prospects, 99–101
 trajectories and risk factors, 101, 102–5
 uniqueness of symptom domains, 98
 outpatient care, 20, 228
 outreach programs, 87, 193, 216, 231
 paliperidone, 155, 159
 paradoxical aging, 96, 106
 paraphrenia, diagnostic criteria, 69
 parental caregivers, 192
 research findings on, 192–93
 parkinsonian symptoms, 62
 Parkinson's disease, 33
 antipsychotic side effects, 35
 Partners in Care, 197
 Patient Centered Medical Home (PCMH), 21
 Patient Outcomes Research Team (PORT), 231
 Patient Protection and Affordable Care Act (ACA), 22, 230
 Patterson, T.L., 175, 176
 PEDAL program, 176
 personal accounts. *See* subjective accounts
 pharmacodynamics, and aging, 157
 pharmacokinetics, and aging, 157
 physical activity
 increasing, 180
 low levels, 179
 physical activity programs, 178, 181, 182, 232
 videogame-based, 183
 physical health care, 20–21
 physical integration, 99
 physical needs, 138
 pimavanserin, 35, 244
 PLAN program, 196
 pneumonia, 82
 police interventions, 191, 195
 polygenic influences, cognition, 57, 58
 polygenic risk score, 58
 polypharmacy, 159
 Positive and Negative Syndrome Scale (PANSS), 98, 99
 positive psychiatry, 114
 defining, 112
 historical background, 112
 interventions in schizophrenia, 114
 outcome in schizophrenia, 113
 psychosocial factors, 113
 positive symptom domains, 97, 98
 positron emission tomography (PET), 57
 posttraumatic stress disorder (PTSD), 139, 140
 potential life lost, 80
 PREMIER lifestyle intervention, 179
 prescribing cascade, 159
 Primary and Behavioral Health Care Integration (PBHCI), 87

	Index	255
Primary Care Access, Referral, and Evaluation (PCARE), 87		
primary diagnosis of schizophrenia		
hospital populations, 16		
primary psychiatric disorders, 28, 146		
examination and assessment, 29		
prisons, 227, 228		
Program of Assertive Community Treatment (PACT), 195		
prolactin, 86		
psychiatric hospitals, 15–16		
psychoeducation, 172		
psychological integration, 99		
psychological needs, 139–40		
psychosis. <i>See also</i> late life psychosis; schizophrenia		
crisis situations, 191		
defining, in epidemiological studies, 3–5		
dementia-related. <i>See</i> dementia		
DSM criteria, 7		
gathering information on symptoms, 4–5		
information from health care registers, 5		
life expectancy, 223, 224		
measurement vs. evaluation, 3		
observational epidemiological literature, 2–3		
primary care, lack of, 21		
recovery model, 208		
symptom severity using DSM-5, 97		
psychosocial functioning. <i>See also</i> social functioning		
positive, 113		
psychosocial interventions, 73, 131, 162, 172, 231–34		
access to mainstream society, 231		
research on, 236		
psychosocial models of care, 87		
psychosocial rehabilitation, 140, 173–78, 184		
CBSST, 176–78		
FAST program, 175–76		
HOPES program, 174–75, 184		
models in review, 178		
PEDAL program, 176		
psychotherapy, 229		
public policy issues, 223–37		
coordination of systems and leadership, 234		
future research, 235–36		
housing and residential care, 226–28, 237		
income supports, 226		
mortality gap and, 224–26, 236		
psychosocial interventions, 231–34		
treatment issues, 228–31		
workforce challenges, 234		
QTc prolongation, 159		
quality of life, 123–24, 207, 224		
depression and, 123, 130		
public policy goal, 236		
subjective, 123		
quetiapine, 35, 37, 159		
cardiovascular risk, 84		
dosing, 162		
selected studies, 154		
raloxifene, 162		
randomized controlled trials (RCTs), 244, 245, 246		
reciprocity, and caring, 190		
recovery model, 96, 208		
recovery prospects in late life schizophrenia, 99–101		
recovery-oriented rehabilitation, 231		
rehabilitation psychosocial. <i>See</i> psychosocial rehabilitation		
recovery-oriented, 231		
rehabilitation programs, 223		
relapse prevention training, 172		
religion, 232		
Remission in Schizophrenia Working Group, 99, 100		
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), 71		
Research Domain Criteria (RDoC), 59		
residential care, 226–28, 237		
drift to, 232		
payment for, 226		
respiratory disorders, 81–82, 88		
mortality risk, 81		
prevalence rates, 82		
revascularization, 84		
reverse-integrated models, 87		
risperidone, 35, 37, 147, 157		
cognition study, 72		
comparison drug, 152		
dosing, 162		
long-acting injectable, 152		
selected studies, 150		
role management, 170		
Sajatovic, M., 171, 172		
Saks, Elyn, 190		
SAMHSA, 234		
SCALE acronym, 177		
scatter beds, 16		
schizoaffective disorder, 31, 38		
schizophrenia, 31, <i>See also</i> early-onset schizophrenia; late life schizophrenia; late-onset schizophrenia; very-late-onset schizophrenia-like psychosis		
across cultures, 212–13		
adverse symptoms, 205		
age-related changes, 55		
biomarkers of aging, 58–60		
cognitive dysfunction. <i>See</i> cognitive dysfunction		
comorbidities in nursing homes, 18		
cross-cultural differences in treatment, 215–17		
diagnosis, 36–37		
direct and indirect costs of, 13		
essence of life, 203		
functional imaging, 56		
genetics, through life, 57–58		
late life psychosis association, 8		
life expectancy, 79, 169		
living life whilst managing, 203		
metabolic syndrome and aging, 63–64		
mortality rates, 6, 20, 79		
neuroimaging in, 55–56		
neuropathology, 60		

- schizophrenia (*cont.*)
 outcomes in. *See* outcome in schizophrenia
 positive psychiatry interventions, 114
 prevalence, 6, 246
 prevalence in developing countries, 212
 public policy issues. *See* public policy issues
 risk factors, 6
 subjective accounts. *See* subjective accounts
 schizophrenia in older age. *See* late life schizophrenia
 schizophrenia-spectrum disorders, 36–40
 schizophreniform disorder, 31
 second generation
 antipsychotics, 34, 62, 147
 older adults, 157
 side effects, 157
 secondary psychotic disorders, 28, 31, 35, 146
 SEER database, 86
 self-appraisals, 123
 self-management. *See* illness self-management
 self-reports, 117, 118
 Seligman, Martin, 112
 sense of belonging, 208
 sensory deficits, 50
 sertraline, 35
 sibling caregivers, 194
 single photon emission computed tomography (SPECT), 57
 skills training, 139
 smoking, 85, 159, 224
 social cognition, 121
 social contact, 142
 social functioning, 103, 117, 124–25
 determinants of, 121–22
 measuring, 117–18
 needs, 140
 qualitative research, 122–23
 quality of life, 123–24
 quantitative research, 118–21
 social integration, 99
 social isolation, 227
 countering, 228, 232
 social rejection, 205, 209
 social roles, 119
 Social Security Disability Insurance, 22, 226
 Social Security Retirement Benefits, 226
 Social Security Trust Fund, 226
 social skills, 120, 140, 142, 231
 social skills training (SST), 176
 social support, 119, 121
 socio-economically disadvantaged, 16
 socioethnodemography, 2
 solving problems module, 177
 spousal caregivers, 194
 SSRIs, 130
 staff
 challenges at work, 234
 selection and training, 142
 Standardized Mortality Ratio (SMR), 79, 80, 81
 start low and go slow, dosing, 161
 stigmatization, 140, 141, 205, 209, 229
 across cultures, 213
 STRIDE program, 179–80
 study design, 3
 subjective accounts, 200–201, 245
 between adversity and personal growth, 204–8
 coping strategies, 203–4
 methodological notes, 201–2
 narrating schizophrenia, 202–3
 searching for a voice, 208–9
 subjective quality of life (SQOL), 123
 substance abuse, 140, 225
 substance/medication induced psychotic disorder, 31, 36
 subsyndromal depression, 129, 131
 successful aging, 96, 101, 124
 Successful Aging Scale, 99
 suicide, 38, 88, 128, 129–30, 223
 preventative measures, 225
 Supplemental Nutrition Assistance Program (SNAP), 226
 Supplemental Security Income (SSI), 226
 survival time, 2
 survivor bias, 89, 113, 124
 survivor effect, 244
 tardive dyskinesia, 61–63, 161, 244
 Targeted Training in Illness Management (TTIM), 171–72, 184
 technologies, innovative, 217–18
 mobile, 87, 185, 217, 248
 telehealth, 87, 185, 248
 telomere length, 59
 tetrabenazine, 62
 thiothixene, 148, 157
 timing of exposure/outcome, 2
 TNF- α biomarker, 59
 traditional healers, 213, 216
 traditional medicine, 215
 transinstitutionalization, 17, 229
 Treatment Advocacy Center (TAC), 195
 two hit hypothesis, schizophrenia, 56
 21st Century Cures Act, 234
 under-prescription, cardiovascular drugs, 84, 86
 under-treatment
 cancer, 86
 cardiovascular disease, 84
 medical disorders, 139
 United Kingdom, caregivers in, 197
 United States
 caregivers in, 196
 late life schizophrenia prevalence, 14, 15
 public policy issues, 223–37
 unmet needs, 136, 137
 aging caregivers, 192
 environmental, 138
 motivation and, 143
 psychological, 139
 psychosocial, 137, 246
 valbenazine, 62, 161
 ventricle to brain ratio (VBR), 55
 ventricles, enlarged, 55
 verbal fluency impairments, 71
 very-late-onset schizophrenia-like-psychosis, 31, 36, 37, 47, 51

Cambridge University Press
978-1-108-72777-8 — Schizophrenia and Psychoses in Later Life
Edited by Carl I. Cohen , Paul D. Meesters
Index
[More Information](#)

	Index	257
cognitive defects, 49		
dementia and, 242		
demographics, 47		
positive and negative symptoms, 48		
treatment, 51		
Veterans' Administration (VA), 230, 237		
videogame-based physical activity program, 183		
violent patient, 191		
visual hallucinations, 33, 212		
visuospatial impairments, 71		
VLOSLP. <i>See</i> very-late-onset schizophrenia-like-psychosis		
wellness programs, 232		
white matter changes, 56, 57		
women. <i>See</i> gender		
workforce challenges, 234		
workforce, selection and training, 142		
World Health Organization (WHO), 27, 212, 215		
Wu, E.Q., 14		
Yarborough, B.J., 179		
ziprasidone, 155, 159		
dosing, 162		